23G(n = 70) | 25G(n = 97) | |||||
---|---|---|---|---|---|---|
No RVH(n = 52) | RVH(n = 18) | p-value | No RVH(n = 76) | RVH(n = 21) | p-value | |
Sex (male/female) | 31 (59.6) | 12 (66.7) | 0.596 | 46 (60.5) | 14 (66.7) | 0.608 |
Age, years (mean ± SD) | 56.94 ± 10.45 | 48.22 ± 11.46 | 0.006 | 53.96 ± 11.85 | 43.19 ± 12.52 | < 0.001 |
Duration of diabetes, years | 10.00 (5.00–17.00) | 5.00 (3.00–9.25) | 0.007 | 12.50 (8.50–17.00) | 6.00 (2.00–15.00) | 0.003 |
Preoperative fasting blood glucose level, mmol/L | 5.88 (4.88–7.44) | 5.27 (3.99–6.97) | 0.149 | 5.93 (5.09–7.06) | 6.04 (4.21–7.97) | 0.646 |
Preoperative systolic blood pressure,mmHg | 137.60 (100–183) | 139.22 (92–187) | 0.702 | 135.03 (88–190) | 140.14 (100–187) | 0.464 |
Serum creatinine, μmol/L | 70.40 (53.33–88.78) | 108.80 (66.78–231.28) | 0.002 | 71.80 (56.08–118.00) | 95.00 (68.80–373.60) | 0.009 |
Urea, mmol/L | 6.47 (5.17–7.58) | 8.14 (5.42–13.36) | 0.066 | 5.88 (4.79–7.81) | 9.40 (5.49–14.04) | 0.005 |
Triamcinolone acetonide usage, n(%) | 48 (92.3) | 15 (83.3) | 0.523 | 45 (59.2) | 14 (66.7) | 0.536 |
Electral-coagulation usage (fibrovascular membrane), n(%) | 10 (19.2) | 2 (11.1) | 0.671 | 6 (7.9) | 1 (4.8) | 0.988 |
Air-fluid exchange, n(%) | 49 (94.2) | 17 (94.4) | 1 | 52 (68.4) | 14 (66.7) | 0.879 |
Pre-pan-retinal photocoagulation, n(%) | 9 (17.3) | 3 (16.7) | 1 | 14 (18.4) | 1 (4.8) | 0.233 |
Anti-vascular endothelial growth drug usage, n(%) | 9 (17.3) | 1 (5.6) | 0.402 | 25 (32.9) | 8 (38.1) | 0.656 |